CA
NZ
UK
AU
IND
US
…
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Arlington Heights, Illinois.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
ENVue Medical Inc. is a publicly listed medical device company; widely available public detail on its specific products and operations is limited. Long-term growth drivers may include aging populations, rising demand for device-led clinical care, and successful commercialization and clinical adoption of any proprietary technologies, which could support revenue expansion. Investors may find the company attractive for exposure to the medtech sector if it appears positioned to convert clinical validation into recurring sales.
Material risks include regulatory and reimbursement uncertainty, strong competition from established medical-technology firms, execution and commercialization risk, and potential need for additional financing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -18.49M | -3.69M | -3.68M | -5.41M | -14.25M |
| Net income | -18.18M | -3.71M | -3.71M | -5.45M | -14.28M |
| Selling general administrative | 7.63M | 3.46M | 3.92M | 3.93M | 5.06M |
| Selling and marketing expenses | 2.49M | 0.72M | 0.86M | 0.96M | 1.10M |
| Gross profit | 0.15M | 1.51M | 1.54M | 0.17M | 0.77M |
| Reconciled depreciation | 0.90M | 0.00M | 0.00M | 0.00M | 0.00M |
| Ebit | -11.73M | -3.69M | -3.44M | -5.41M | -14.25M |
| Ebitda | -10.84M | -3.69M | -3.44M | -5.41M | -14.25M |
| Depreciation and amortization | 0.90M | 0.00M | 0.00M | 0.00M | 0.00M |
| Operating income | -11.73M | -3.58M | -3.44M | -5.01M | -5.68M |
| Other operating expenses | 14.29M | 6.14M | 5.72M | 5.76M | 7.38M |
| Interest expense | - | 0.14M | 0.25M | 0.35M | 0.00M |
| Tax provision | -0.31M | 0.02M | 0.03M | 0.04M | 0.03M |
| Net interest income | 4.40M | -0.10M | -0.25M | -0.40M | -0.05M |
| Income tax expense | -0.31M | 0.02M | 0.03M | 0.04M | 0.03M |
| Total revenue | 2.55M | 2.56M | 2.28M | 0.75M | 1.70M |
| Total operating expenses | 11.89M | 5.09M | 4.97M | 5.18M | 6.45M |
| Cost of revenue | 2.40M | 1.05M | 0.75M | 0.58M | 0.93M |
| Total other income expense net | -6.76M | -0.10M | -0.25M | -0.40M | -8.57M |
| Net income from continuing ops | -18.18M | -3.71M | -3.71M | -5.45M | -14.28M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 41.12M | 3.63M | 6.67M | 5.88M | 8.62M |
| Intangible assets | 4.38M | - | - | - | - |
| Other current assets | 0.17M | 0.12M | 0.05M | 0.61M | 0.17M |
| Total liab | 7.63M | 3.00M | 2.69M | 2.65M | 2.31M |
| Total stockholder equity | 33.50M | 0.63M | 3.99M | 3.23M | 6.31M |
| Other current liab | 4.48M | 2.61M | 2.27M | 2.15M | 1.72M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.03M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -90.48M | -69.80M | -66.10M | -62.38M | -56.94M |
| Good will | 29.08M | 0.00M | - | - | - |
| Cash | 4.22M | 0.75M | 3.28M | 2.71M | 7.74M |
| Total current liabilities | 6.66M | 2.72M | 2.45M | 2.32M | 1.90M |
| Current deferred revenue | 0.17M | 0.01M | 0.05M | 0.02M | 0.04M |
| Net debt | -3.03M | -0.64M | -3.28M | -2.63M | -7.69M |
| Short term debt | 1.17M | 0.05M | 0.01M | 0.08M | 0.05M |
| Short long term debt | 1.08M | - | - | - | - |
| Short long term debt total | 1.20M | 0.12M | 0.01M | 0.08M | 0.05M |
| Other stockholder equity | 124.06M | 70.50M | 70.15M | 65.63M | 63.16M |
| Total current assets | 7.27M | 3.33M | 6.49M | 5.61M | 8.34M |
| Net receivables | 0.54M | 0.27M | 0.42M | 0.11M | 0.26M |
| Inventory | 2.34M | 2.19M | 2.73M | 2.17M | 0.17M |
| Accounts payable | 0.72M | 0.05M | 0.14M | 0.07M | 0.09M |
| Accumulated other comprehensive income | -0.08M | -0.08M | -0.07M | -0.02M | 0.06M |
| Non currrent assets other | 0.14M | 0.17M | 0.17M | 0.18M | 0.23M |
| Non current assets total | 33.85M | 0.30M | 0.19M | 0.27M | 0.28M |
| Capital lease obligations | 0.12M | 0.12M | 0.01M | 0.08M | 0.05M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total cashflows from investing activities | 0.09M | -0.00M | -0.00M | -0.00M | -0.00M |
| Net borrowings | -1.42M | 0.00M | - | - | 0.00M |
| Total cash from financing activities | 12.79M | 0.00M | 4.22M | 2.09M | 4.58M |
| Net income | -18.18M | -3.71M | -3.71M | -5.45M | -14.28M |
| Change in cash | 3.50M | -2.53M | 0.57M | -5.02M | 0.20M |
| Begin period cash flow | 0.75M | 3.28M | 2.71M | 7.74M | 7.53M |
| End period cash flow | 4.25M | 0.75M | 3.28M | 2.71M | 7.74M |
| Total cash from operating activities | -9.37M | -2.52M | -3.60M | -7.04M | -4.37M |
| Issuance of capital stock | 19.09M | 0.00M | 4.21M | 2.09M | 0.00M |
| Depreciation | 0.90M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | 0.25M | 0.54M | -0.56M | -2.00M | -0.03M |
| Change to account receivables | -0.28M | 0.22M | -0.31M | 0.19M | -0.17M |
| Sale purchase of stock | -5.00M | 0.00M | - | - | - |
| Other cashflows from financing activities | 0.01M | - | - | - | -0.39M |
| Capital expenditures | 0.06M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 1.66M | 0.73M | -0.32M | -2.31M | -0.49M |
| Stock based compensation | 0.00M | 0.36M | 0.29M | 0.35M | 0.38M |
| Other non cash items | 6.62M | 0.10M | 0.14M | 0.36M | 10.03M |
| Free cash flow | -9.43M | -2.52M | -3.60M | -7.04M | -4.37M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FEED ENvue Medical Inc. |
-0.05 19.23% |
0.21 | - | - | 1.94 | 0.15 | 0.76 | 0.43 |
| ABT Abbott Laboratories |
-0.03 0.03% |
109.93 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-3.04 2.90% |
101.80 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-9.21 2.75% |
325.87 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-2.15 4.12% |
49.85 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Arlington Heights, Illinois.
762 W. Algonquin Road, Arlington Heights, IL, United States, 60005
914 233 3004
31
| Name | Title | Year Born |
|---|---|---|
| Dr. Doron Robert Besser M.D. | CEO, President & Director | 1969 |
| Ms. Rita Silberberg | Executive VP of Finance, Chief Accounting Officer & Corporate Secretary | 1975 |
| Ms. Lindsey Harrison | Vice President of Sales | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...